Overview
Location
United States, Massachusetts, Waltham
Employees
1-10
Total raised
$12.18M
Founded date
2015
Funding Rounds 2
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
| Jan 8, 2014 | Series B round | $3.58M |
Mentions in press and media 7
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Mar 30, 2016 | ImmuneXcite Completes $8.6M Series A-1 Financing | ImmuneXcite, a Lexington, Mass.-based biopharmaceutical company focused on developing transformative immuno-oncology products that utilize the power of both the innate and adaptive immune response, completed an $8.6m Series A-1 financing. B... |
| Mar 30, 2016 | ImmuneXcite Closes $8.6M Series A-1 Financing | LEXINGTON, MA, Biopharmaceutical company focused on developing transformative immuno-oncology products announced the completion of an $8.6 million Series A-1 financing. >> Click here for more funding data on ImmuneXcite >> T... |
| Jan 8, 2014 | ImmuneXcite Secures $3.58M in Second Funding | ImmuneXcite, a Lexington, MA-based biopharmaceutical company, secured $3.58m in a second funding round. Backers included new and existing investors. The round is in addition to the $2.42m the company raised in 2011 in its first round of fin... |
| Jan 7, 2014 | ImmuneXcite Secures $3.58M Series B Funding | LEXINGTON, MA, Biopharmaceutical company focused on developing the next generation of monoclonal antibodies for cancer employing a neutrophils based immunotherapy platform, today announced it has secured $3.58M in second-round financing. ... |
| Jan 7, 2014 | Biopharma using fungal carbohydrate for innovative cancer immunotherapy raises $3.6M | The funding will help the company advance its technology toward an investigational new drug filing. Among the company’s backers are Massachusetts Technology Transfer Center, Deshpande Center for Technological Innovation at the Massachusetts... |
| Biopharma using fungal carbohydrate for innovative cancer immunotherapy raises $3.6M | Biopharma startup ImmuneXcite is developing an immunotherapy to treat cancer that depends an innovative catalyst — a fungal carbohydrate. The life science innovation relies on neutrophils, white blood cells that represent the body’s first d... |
Reviews 0
FAQ about ImmuneXcite
When was ImmuneXcite founded?
ImmuneXcite was founded in 2015.
How much funding has ImmuneXcite raised?
ImmuneXcite has raised $12.18M in total across 2 funding rounds.
What funding rounds has ImmuneXcite raised?
Parsers VC lists 2 funding rounds of ImmuneXcite, among them a Series B round of $3.58M on Jan 8, 2014.
What has the press written about ImmuneXcite?
Parsers VC has collected 7 articles mentioning ImmuneXcite, among them “ImmuneXcite Completes $8.6M Series A-1 Financing” (Mar 30, 2016) and “ImmuneXcite Closes $8.6M Series A-1 Financing” (Mar 30, 2016).
Is ImmuneXcite still active?
ImmuneXcite is probably closed: its latest activity on Parsers VC dates from Mar 30, 2016.